- Crest Toothpaste (BOGOF)
- Oranges (BOGOF)
- Oreo Cookies $2.99 / pack.
So what exactly is “BOGOF”? It basically stands for buy one get one free. That is my lovely wife’s definition, as she goes out on a mission to save money for the household. What I define BOGOF as, is basically opening up of my fridge to a Florida orange farm, or opening up my freezer to about 100 lbs of chicken breast packs sliding away and landing on my feet at 6am.
Mr.Greenblatt’s system is very simple and I decided to try this out. His system is to buy stocks with high earnings yield (a company’s earnings relative to the share price) and a high return on capital (how much a company earns based on its investments in capital, stuff like machines, delivery trucks, robots, and such). I am somewhat simplifying his formula, as he uses a slightly different formula for earnings yield and return on capital to level out differences in taxation between companies. You can read more about the details of his approach in the appendix section of the book. The system requires an investor to buy sets of 5 to 7 stocks every quarter until you have about 20 to 30 stocks after one year. As each stock matures to the one year mark, you need to dump that set, and buy a new set of stocks based on the same set of criteria. He has made it easier for the average investor by creating a site which returns a set of stocks which pass these criteria daily (http://www.magicformulainvesting.com/).
He back tested this formula over the last 17 years with great success, earning returns of over 30%. That is quite impressive. So impressive I decided to give it a shot with my portfolio. The problem with the magic formula web site list is that it is not ranked in the order in which the book describes, and his return on capital data values are aggregated into quartile buckets. His list is ranked in alphabetical order so I can’t really tell which stock ranks at the top. So I decided to run similar criteria by doing the leg work myself and see how many companies overlapped the list from the magic formula site. Using a stock screener, I set it up using the following set of criteria: - 5 to 15X P/E (trailing twelve months). Picking the stocks with the lowest P/E ratio is pretty much the high earnings yield definition Mr.Greenblatt speaks about in his book.
- Return on Assets (ROA) > 20%. This is similar to the high return on capital criteria the book describes.
- Removed all international companies (ADR’s) and ETF’s
You can download to see the complete list. To get the ranking as the book described, I sorted by P/E ratio from smallest to largest and assigned the rank to each stock starting with 1. I then sorted the same list but this time by return on assets from largest to smallest and assigned the rank to each stock starting with 1. I summed up both columns to get the final score for each stock and sorted the list again by this new summed up column.
As I cruised down my list there were a few names I recognized (Coach, Moody’s, Herman Miller, etc.). I then cruised over to Mr.Greenblatt’s list to find some overlap, but not all. The differences exist because of the slight variations in the formulas we used for earnings yield and return on capital. That’s ok though because the concept is relatively the same and I needed to see that ranking. It was time to make my first set of picks for my portfolio. I walked down the list looking into each company’s story, what their business was, and how strong it was especially in light of the worsening economic picture in the US. Following the system, I had $2500 to spend ($10,000 divided by 4 quarters) in the first quarter of 2008. I decided to pick 5 companies so I would end up with 20 stocks by year end. The following is my first set of buys that I made on Jan.16.2008:
| Symbol | Company | Quantity Purchased | Purchase Price |
| NTRI | NutriSystem Inc. | 21 | 23.65 |
| DST | DST Systems Inc. | 7 | 73.60 |
| TRMS | Trimeris Inc. | 70 | 7.01 |
| IVAC | Intevac Inc. | 43 | 11.37 |
| PCU | Southern Copper Corporation | 6 | 88.98 |
Each bit of analysis takes some time, so I’m already behind. As my wife proclaims, it’s BOGOF time! I need to start making my shopping list for the 2nd quarter. Happy trails… you’ll need it in this punishing environment.
4 comments:
I like all the picks EXCEPT Southern Copper. The numbers probably check out on Southern but it is 75% owned by Grupo Mexico. Grupo Mexico has a rather checkered history of labor problems and other litigation.
Interesting. I did not know about the labor troubles. I'll have to check this out. I'll have a full analysis on Southern Copper in a few weeks. It will take me some time to do the write up.
Thanks
TRMS is in an interesting situation, and I don't think they fit well as part of a screen strategy tracking portfolio because things are far from business as usual there. They're a biotech company that developed and marketed a first-in-class HIV treatment, but recently the future has become less clear for this company. Pressing issues:
*HealthCor has been buying as much of the company's shares as possible, and recently demanded 2 seats on TRMS' board. This group has been applying a great deal of pressure on TRMS to put itself up for sale.
*In December '07 TRMS announced that they will no longer perform R&D and will lay off employees involved in it. They're profitable because of their HIV drug Fuzeon (which is super cool, by the way), but cutting their R&D department means they're pretty much planning on a) coasting on Fuzeon sales (not feasable for long) or b) selling the company.
*TRMS has had 4 CEOs in the past 12 months. Martin Mattingly, the current CEO, was brought hired in November. Notably, he will get a bonus if TRMS is sold in the next year.
*In November, Novartis filed a patent infringement lawsuit against TRMS and their partner Roche over Fuzeon.
If it weren't for the lawsuit it'd be a simple matter of calculating a fair value for TRMS by plugging estimated Fuzeon sales into a DCF model, but the lawsuit really muddies things. Potential buyers would be wise to wait and see how it goes, and with the intense competition in the HIV field the extra time may end up costing TRMS. Drugs have a limited lifespan on the market before something else comes along, and Fuzeon sales dropped 9% in the last quarter.
Thanks PDTBiotech,
I had picked TRMS as part of my screen test and I needed to start out diversifying off the bat. You're right about biotech not fitting well within DCF, it's not as simple as pumping out widgets. It does however force me to cover an area that I am not familiar with (Biotech) which was one of "side effect " goals.
I still need to finish up my detailed write ups on PCU, IVAC, and get to TRMS.
Thanks for the post.
Post a Comment